Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as a first-line treatment for metastatic squamous non-small cell lung cancer in China.

ABSTRACT:

Objectives

Penpulimab is a novel programmed death-1 (PD-1) inhibitor that has been approved in China for use in combination with chemotherapy as a first-line treatment for locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC). However, the cost-effectiveness of this treatment in China remains to be determined. In this study, we aimed to assess the cost-effectiveness of penpulimab combined with paclitaxel and carboplatin for metastatic sq-NSCLC.

Design

Based on the AK105-302 trial (NCT03866993), a Markov model was created to evaluate the disease progression of metastatic sq-NSCLC patients over 10 years. The model included progression-free survival, progressive disease and death. The utility values were derived from published literature. Sensitivity stu

SUBMITTER: Wang L 

PROVIDER: S-EPMC11883829 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature